IDiyas

For the Inventor, By the Inventor

Fishers, IN, United States of America

Daryl Lynn Smith

USPTO Granted Patents = 13

 

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 243(Granted Patents)


Location History:

  • Salt Lake City, UT (US) (2000 - 2003)
  • Fishers, IN (US) (2006 - 2023)

Company Filing History:

goldMedal7 out of 4,442 
 
Eli Lilly and Company
 patents
silverMedal6 out of 93 
 
Nps Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 1,500 
 
Astrazeneca Ab
 patents
where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 11773067 - (Trifluoromethyl)pyrimidine-2-amine compounds (2023-10-03),
2. 11414389 - (trifluoromethyl)pyrimidine-2-amine compounds (2022-08-16),
3. 10227310 - Ghrelin 0-acyl transferase inhibitors (2019-03-12),
4. 7655641 - Sulfonamide derivatives as PPAR modulators (2010-02-02),
5. 7595339 - CB1 modulator compounds (2009-09-29),
6. 7282501 - Modulators of peroxisome proliferator activated receptors (PPAR) (2007-10-16),
7. 7276516 - CB1 antagonist compounds (2007-10-02),
8. 7112595 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists (2006-09-26),
9. 7053104 - Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases (2006-05-30),
10. 6660753 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists (2003-12-09),
11. 6617358 - Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses (2003-09-09),
12. 6429207 - Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases (2002-08-06),
13. 6017965 - Compounds active at a novel site on receptor-operated calcium channels (2000-01-25),

Title: Innovator Spotlight: Daryl Lynn Smith

Introduction:

Daryl Lynn Smith, a leading inventor based in Fishers, IN, has made significant contributions to the field of pharmaceuticals with a total of 13 patents to his name. His innovative work has focused on developing compounds that are revolutionizing the treatment of various types of pain.

Latest Patents:

Smith's latest patents include the groundbreaking "(Trifluoromethyl)pyrimidine-2-amine compounds." These compounds, represented by Formula I, or a pharmaceutically acceptable salt thereof, have shown great promise in treating pain, such as chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.

Career Highlights:

Having worked at esteemed companies like Eli Lilly and Company and Nps Pharmaceuticals, Inc., Smith has honed his skills and expertise in the pharmaceutical industry. His experience and dedication have played a pivotal role in bringing cutting-edge solutions to the market.

Collaborations:

Throughout his career, Smith has collaborated with accomplished professionals in the field. Notable colleagues include Scott T Moe and Bradford C Van Wagenen, who have worked alongside Smith in the development of innovative pharmaceutical compounds.

Conclusion:

Daryl Lynn Smith's remarkable journey as an inventor showcases his unwavering commitment to advancing healthcare through groundbreaking inventions. With a robust portfolio of patents and a history of successful collaborations, Smith continues to be a driving force in the pharmaceutical industry, shaping the future of pain management.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…